Company Overview#
AAVATAR Therapeutics is a gene therapy company that designs custom AAV vectors for rare and hard-to-treat diseases. It pairs a machine learning-driven capsid engineering platform with its own manufacturing (CMC) capability. It positions itself as a next-generation AAV delivery and production partner.
Technology & Product#
The core is a machine learning-driven AAV engineering platform that designs large libraries of capsid sequences, screens them with next-generation sequencing and predictive models, and refines candidates through repeated learning cycles. This finds AAV variants with better tissue targeting. The company adds cell- and tissue-specific promoter engineering and a full CMC pipeline that covers vector design, cell-line optimization, quality control, and scale-up. Together this supports both novel capsid discovery and high-yield production.
Market & Use Cases#
The platform targets tissue-specific in-vivo gene delivery for rare and intractable diseases. Disclosed pipeline areas include lysosomal storage diseases, hereditary hearing loss, and preclinical central nervous system disorders. The company offers capsid and promoter design, engineering, and production as a service to pharmaceutical and research partners.
Traction & References#
AAVATAR raised a KRW 5 billion Series A in late 2023, led by TS Investment with Shinhan Capital, Smilegate Investment, and Wonik Investment Partners joining(BioSpectator). It was selected as a government Baby Unicorn company in 2024(AAVATAR). AAVATAR runs research collaborations with academic and medical partners including Ewha Womans University, Yonsei University, Seoul National University, and Samsung Medical Center(AAVATAR).
Collaboration Relevance#
AAVATAR is a natural fit for R&D collaborations and material transfer agreements (MTAs) with pharmaceutical companies and research institutions. Its service model covers custom capsid and promoter design plus production, which suits partners that need tissue-specific delivery. The company is focused on delivery for central nervous system and cardiac indications, and its confirmed CNS preclinical work supports this direction.